News

Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35^th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis

Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today closed its transaction to acquire key assets from

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the

QuidelOrtho Corporation (NASDAQ: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its

Agilent Technologies Inc. (NYSE: A) today announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the

Humana Inc. (NYSE: HUM) and USAA Life Insurance Company (USAA Life) announced a new Medicare Advantage plan designed with veterans in mind to provide a robust coverage option that complements

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the publication of its first paper describing the

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2022, the period ended August 31, 2022, after the close

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2022 results on Monday, October 31, 2022, after the close of the market. Acadia will conduct a

Agilent Technologies Inc. (NYSE: A) today announced the World Economic Forum’s Global Lighthouse Network has named Agilent’s facility in Singapore a Fourth Industrial Revolution (4IR) leader for

Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website